Clinical Trial Update: A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial to evaluate the efficacy and safety of VSA003 in Chinese patients with Homozygous Familial Hypercholesterolemia is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• VSA003

Snippet

Sponsor: Visirna Therapeutics HK Limited | Conditions: Homozygous Familial Hypercholesterolemia (HoFH) | Phase 3 | Status: NOT_YET_RECRUITING